aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Revance Therapeutics, founded with a mission to revolutionize patient and physician experiences in dermatology and aesthetic medicine, focuses on developing innovative biopharmaceutical products. The company's flagship product, DAXXIFY®, is a long-lasting, peptide-powered treatment for frown lines and cervical dystonia. Revance aims to set new standards in healthcare by offering advanced therapeutic solutions across the United States.
Notable figures associated with Revance include its leadership team and key investors who have supported its growth and innovation. The company has achieved significant milestones, such as the successful launch of DAXXIFY® for both aesthetic and therapeutic uses. Revance's impact is evident in its commitment to enhancing patient care and its expanding presence in the U.S. therapeutics market.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Biopharmaceuticals
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Transactional, Recurring
Customer Type(s)
Consumers
Geographic Exposure
United States
When was Revance Therapeutics founded?
Revance Therapeutics was founded in 1999.
Where is Revance Therapeutics's headquarters located?
Revance Therapeutics's headquarters is located in Newark, NJ, US.
When was Revance Therapeutics's last funding round?
Revance Therapeutics's most recent funding round was for $200M (USD) in September 2022.
How many employees does Revance Therapeutics have?
Revance Therapeutics has 534 employees as of Feb 6, 2024.
How much has Revance Therapeutics raised to-date?
As of July 05, 2023, Revance Therapeutics has raised a total of $1.6B (USD) since Sep 12, 2022.
Add Comparison
Total Raised to Date
$1.6B
USD
Last Update Sep 12, 2022
Last Deal Details
$200M
USD
Sep 12, 2022
Post Ipo Equity
Total Employees Over Time
534
As of Feb 2024
Revance Therapeutics Address
Newark,
New Jersey
07108
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts